Experienced venture capitalist / pharma manager joins Apeiron’s business development team

APEIRON Biologics AG (Apeiron) today announced that Patrick Burgermeister, a seasoned venture capital and pharma manager will play a leading role in the company’s business development activities. He will be engaged in identification and evaluation of new projects, in-licensing/out-licensing activities, portfolio assessment and sourcing new financing opportunities. Press release Presseaussendung

January 10, 2011
No Comments
Apeiron acquires rights to new clinical stage project

APEIRON Biologics AG (Apeiron) today announced that, as part of its effort to broaden its current project portfolio, it has concluded an agreement with Polymun Scientific GmbH (Polymun) granting Apeiron exclusive rights to recombinant human Super Oxide Dismutase (SOD) for treatment of various inflammatory conditions. Press release Presseaussendung  

November 4, 2010
No Comments
Pain alliance with Evotec

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) and APEIRON Biologics AG today announced that they have entered into a collaboration to identify small molecule modulators of DREAM (Downstream Regulatory Element Antagonistic Modulator), a novel target involved in perception of various pain mechanisms. Press release Presseaussendung

October 27, 2010
No Comments
European Biotechnica Award 2010

Apeiron among the three finalists nominated for the EUROPEAN BIOTECHNICA AWARD 2010. Other finalists are listed companies Addex Pharmaceuticals (Switzerland) and Galapagos Genomics (Belgium).

October 4, 2010
No Comments
Biotech-Pharma Partnerships

LISA VR Press Talk: current partnerships between biotech and pharma in Vienna. LISA VR Press Talk

April 30, 2010
No Comments
Exclusive Licence Agreement with GSK

Apeiron Biologics AG (Apeiron) today announced the signing of an agreement granting GlaxoSmithKline (GSK) exclusive rights to APN01 (recombinant human Angiotensin Converting Enzyme 2, rhACE2), an enzyme biotherapeutic currently in Phase 1 development for the treatment of the Acute Respiratory Distress Syndrome (ARDS). Press release Presseaussendung  

February 3, 2010
No Comments
Manfred Reichl awarded Business Angel of the Year

On Nov. 17th, one of our major shareholders, business angel and Chairman of the Supervisory Board, DDr. Manfred Reichl has received the award “Business Angel of the Year“. Congratulations!  

November 17, 2009
No Comments